title: Caspase-dependent and -independent induction of phosphatidylserine externalization during apoptosis in human renal carcinoma Cak(1)-1 and A-498 cells.
abstract: Renal cell carcinoma is the most common neoplasm occurring in the kidney and is largely resistant to current chemotherapy. Understanding the mechanisms involved in renal carcinoma cell death may lead to novel and more effective therapies. In Cak(i)-1 renal cancer cells, using phosphatidylserine externalization as a marker of apoptosis, the anti-cancer drugs 5-fluorouracil (5-FU), and its pro-drugs, doxifluridine (Dox) and floxuridine (Flox) proceeds via a caspase-dependent mechanism. In contrast, phosphatidylserine externalization produced by staurosporine in the renal cancer cell lines Cak(i)-1 and A-498 proceeds via a caspase-independent mechanism. That is, the pan caspase inhibitor N-benzyloxycabonyl-Val-Ala-Asp-fluoromethylketone (ZVAD) did not ameliorate annexin V binding, cell shrinkage or changes in nuclear morphology. Subsequent experiments were conducted to determine mediators of phosphatidylserine externalization, using annexin V binding, when caspases were inhibited. Prior treatment of A-498 cells with cathepsin B (CA74 methyl ester), cathespsin D (pepstatin A) or calpain inhibitors (calpeptin, E64d) in the presence or absence of ZVAD did not ameliorate annexin V binding. The endonuclease inhibitor aurintricarboxylic acid (ATA), phospholipase A(2) inhibitor bromoenol lactone (BEL), protein synthesis inhibitor cycloheximide (CH) and chloride channel blockers niflumic acid (NFA) and 5-nitro-2-(3-phenylpropylamino) benzoic acid (NPPB) all had no effect on staurosporine-induced annexin V binding in A-498 cells either in the presence or absence of ZVAD. We also modulated sphingomyelin and the de novo pathways of ceramide synthesis and found no amelioration of staurosporine-induced annexin V binding in A-498 cells either in the presence or absence of ZVAD. These results indicate that 5-FU, Dox and Flox induce externalization of phosphatidylserine during apoptosis in Cak(i)-1 renal cancer cells primarily through a caspase-dependent mechanism and that externalization of phosphatidylserine during apoptosis produced by staurosporine in the renal cancer cell line A-498 is independent of many of the common signaling pathways known to be involved in this process.
authors.affiliation: Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA. e.lock@ljmu.ac.uk
authors.forename: Edward A
authors.initials: EA
authors.lastname: Lock
authors.forename: Celia J
authors.initials: CJ
authors.lastname: Reed
authors.forename: Gilbert R
authors.initials: GR
authors.lastname: Kinsey
authors.forename: Rick G
authors.initials: RG
authors.lastname: Schnellmann
mesh_terms: D000590:Amino Acid Chloromethyl Ketones / Q000494:pharmacology; D000814:Aniline Compounds / Q000494:pharmacology; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D019817:Benzoic Acid / Q000494:pharmacology; D001597:Benzylidene Compounds / Q000494:pharmacology; D002154:Calpain / Q000037:antagonists & inhibitors; D020169:Caspases / Q000378:metabolism*; D002401:Cathepsin B / Q000037:antagonists & inhibitors; D002402:Cathepsin D / Q000037:antagonists & inhibitors; D045744:Cell Line, Tumor; D048429:Cell Size / Q000187:drug effects; D002518:Ceramides / Q000037:antagonists & inhibitors; D002945:Cisplatin / Q000494:pharmacology; D005089:Exocytosis / Q000187:drug effects / Q000502:physiology; D037341:Fumonisins / Q000494:pharmacology; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism / Q000473:pathology; D009281:Naphthalenes / Q000008:administration & dosage / Q000494:pharmacology; D009544:Niflumic Acid / Q000494:pharmacology; D009579:Nitrobenzoates / Q000494:pharmacology; D010718:Phosphatidylserines / Q000378:metabolism*; D011753:Pyrones / Q000008:administration & dosage / Q000494:pharmacology; D013108:Sphingomyelin Phosphodiesterase / Q000037:antagonists & inhibitors; D019311:Staurosporine / Q000494:pharmacology; D014315:Triterpenes / Q000494:pharmacology
chemical_list: C508668:3beta-hydroxy-12-oleanen-27-oic acid; D000590:Amino Acid Chloromethyl Ketones; D000814:Aniline Compounds; D000964:Antimetabolites, Antineoplastic; D001597:Benzylidene Compounds; D002518:Ceramides; D037341:Fumonisins; C468773:GW 4869; D009281:Naphthalenes; D009579:Nitrobenzoates; D010718:Phosphatidylserines; D011753:Pyrones; D014315:Triterpenes; C096713:benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; C058176:5-nitro-2-(3-phenylpropylamino)benzoic acid; C056933:fumonisin B1; D009544:Niflumic Acid; C068314:6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one; D019817:Benzoic Acid; D013108:Sphingomyelin Phosphodiesterase; D002154:Calpain; D020169:Caspases; D002401:Cathepsin B; D002402:Cathepsin D; D019311:Staurosporine; D002945:Cisplatin